>>I would probably step up to buy some OSIP even before that. (I lasted owned it in Jan 05.) As previously posted, I’m looking for the Lucentis ANCHOR data to be the last hammer to create an even better buying opportunity.<<
I am stepping up Thursday. Will put in a limit order at $23.50 and write some 06 puts.
I think Tarceva sales will reaccelerate in 2006 due to the Medicare drug plan. The stock price should follow as the IMS data starts showing that renewed sales growth.
What a coincidence...me too. Maybe bio night owls think alike. For a company down as much as OSIP is from the beginning of the year, this month and December are the absolute worst months to go in a slump, because the tax-loss selling exacerbates the plunge. Big risk for most biotechs right now, but also could be setting up for a snapback rally.
Market Data 
Markets 
AI
